FDA Grants Limited Approval for Moderna's New COVID-19 Vaccine
The FDA has granted limited approval to Moderna's lower-dose Covid-19 vaccine, mNEXSPIKE, for adults 65+ and at-risk individuals aged 12-64 who have previously been vaccinated. The vaccine, intended as an alternative for those preferring a lower dose, is not for young, healthy adults and is expected to be available in the US for the 2025-26 respiratory season. The approval follows recent restrictions on vaccine eligibility and approval criteria.